2Harris N L,Jaffe E S, Stein H,et al. A revised European-American classification of lymphoid neoplasm:a proposal from the International Lymphoma Study Group[J]. Blood, 1994,84 : 1361-- 1392.
3Amytage J O,Weisenburger D D. New approach to classifying non-Hodgkin’s lymphoma:clinincal features of the major histologic subtypes. Non-Hodgkin’s Lymphoma Classification Projet [J］. J Cli Oncol, 1998,16 : 2780-- 2795.
4Takakuwa T, Hongyo T, Syaifudin M,et al. Microsatellite instability and kras, p53 mutations in thyroid lymphoma[J]. Jpn J Cancer Res, 2000,91(3) :280--286.
5Hough R E, Goepel J R, Alcock H E,et al. Copy number gain at 12q12-14 may be important in the transformation from follicular lymphoma to diffuse large B cell lymphoma[J]. Br J Cancer, 2001,84(4) ,499--503.
6Dupin N, Diss T L, Kellam P, et al.HHV-8 is associated with a plasmablastic variant of Castleman disease that islinked to HHV-8-positive plasmablastic lymphoma [J]. Blood, 2000,95: 1406-1412.
7Egelhard M, Brittinger G, Huhn D, et al. Subclassification of diffuse larg Bcell lymphomas according to the Kiel classification: distinction of centerblastic and immunoblastic lymphornas is a significant prognostic risk factor[J].Blood, 1997,89,2291 -- 2797.
8Jaffe E S, Harris N L, Stein H,et al.Word Health Organization Classification of Tumors: Pathology and Genetics of Tumors of Haemotopoietic and Lymphoid Tissues [M]. Prance : IARC Press Lyon,2001. 171 -- 174.
9Delabie J,Vandenberghe E,Kennes C,et al. Histocyte-rich B-cell lymphoma. A distinct clinicalpathological entity possibly related to lymphocyte predominant Hodgkin's disease, paragranuoma substype[J], Am J Surg Pat hol, 1992 ,16: 37--48.
10Ramsay A D, Smith W J ,lsaacson P G. T-cell-rich B-cell lymphoma[J]. Am J Surg Patho1,1998,12:433-- 443.
二级参考文献9
1Osterman B, Cavallin-Stahl E, Hagberg H, et al. High-grade non-Hodgkin′s lym phoma stage I. A retrospective study of treatment, outcome and prognostic factor s in 213 patients. Acta oncol,1996,35:171-177.
2Harris NL,Jaffe ES, Diebold J et al. The World Health Organi zation classification of neoplastic diseases of the haematopoietic and lymphoid tissue. Report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Histopathology,2000, 36:69-86.
3Lennert K, Feller AC. Histopathology of non-Hodgkin′s lymph oma (based on the updated Kiel classification ).Berlin:Springer-Verlag, 1992.
4Lo Coco F, Ye BH, Lista F, et al. Rearrangements of the BCL -6 gene in diffuse large cell non-Hodgkin′s lymphoma. Blood, 1994,83:1757-1759.
5Offit K, Lo Coco F, Louie DC, et al. Rearrangement of the bcl- 6 gene as a prognostic marker in diffuse large-cell lymphoma. N Engl J Med, 1994, 331:74 -80.
6Flenghi L,Ye BH, Fizzotti M, et al. A specific monoclonal antibody (PG-B6) detects expression of the BCL-6 protein in germinal center B cells. Am J Pathol ,19 95,147:405-411.
7Ye BH, Lista F, Lo Coco F, et al. Alterations of a zinc finge r-encoding gene, BCL-6,in diffuse large-cell lymphoma. Science, 1993,262:74 7-750.
8Flenghi L, Bigerna B, Fizzotti M ,et al. Monoclonal antibodi es PG-B6a and PG-B6p recognize, respectively, a highly conserved and formol-resistant epitope on t he human BCL-6 protein amino-terminal region. Am J Pathol ,1996,148:1543-1555 .
9Carbone A, Gloghini A,Gaidano G, et al. BCL-6 protein expressi on in human peripheral T-cell neoplasms is restricted to CD30+ anaplastic large-cell lymphomas. Blood , 1997,90:2445-2450.
4Zhang H, Kobayashi R, Galaktionov K, et al. P19Skpl and p45Skp2 are essential elements of the cyclin A-CDK2 S phase kinas[J]. Cell, 1995,82(6) :915 - 925.
5Cunningham MA, Zhu Q, Hammond JM. Foxola can alter cell cycle progression by regulating the nuclear localization of p27kip in granulosa cells [J]. Mol Endocrinol,2004,18 (7): 1756- 1767.
6Seki R, Okamura T, Koga H, et al. Prognostic significance of the F- Box protein Skp2 expression in diffuse large B-cel lymphoma[ J]. Am J Hematol,2003,73(4) :230 - 235.
7Traub F, Mengel M, Lack HJ, et al. Prognostic impact of Skp2 and p27 in human breast cancer[J]. Breast Cancer Res Treat, 2006, 99 (2):185- 191.
8Harada K, Supriatno, Kawagnchi S, et al. High expression of S-phase kinase associated protein2 (Skp2) is a strong prognostic marker in oral squamous cell carcinoma patients treated by UFT in combination with radiation[J]. Anticancer Res, 2005,25(3c) :2471 - 2475.
9Takanami I. The prognostic value of overexpression of Skp2 mRNA in non-small cell lung cancer[J]. Oncol Rep, 2005,13(4) :727 - 731.
10Woenckhaus C, Maile S, Uffmann S, et al. Expression of Skp2 and p27KIPI in naevi and malignant melanoma of the skin and its relation to clinical outcome[J]. Histol Histopathol, 2005,20(2) :501 - 508.
